Fig. 6: Inhibition of self-derived exosome secretion or exogenous exosome uptake enhances HCC metastasis and recurrence in vivo. | Cell Death & Disease

Fig. 6: Inhibition of self-derived exosome secretion or exogenous exosome uptake enhances HCC metastasis and recurrence in vivo.

From: HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway

Fig. 6

a Comparison of tumour size and weight in nude mice subcutaneously implanted with siSCR/MHCC97H or siRab27a/MHCC97H cells (n = 4/group). b The lung metastatic ability of human tumours in the siSCR/MHCC97H cell-injection and siRab27a/MHCC97H cell-injection groups visualised using H&E staining, magnifications = ×20, ×40. The arrow indicates the metastatic foci. c Western blot analysis of Rab27a and EMT markers in subcutaneously formed tumours in the siSCR/MHCC97H cell-injection and siRab27a/MHCC97H cell-injection groups. d Immunohistochemical assay of E-cadherin and N-cadherin in subcutaneously formed tumours in the siSCR/MHCC97H cell-injection and siRab27a/MHCC97H cell-injection groups. e The intrahepatic metastatic ability of siRab27a/MHCC97H and siSCR/MHCC97H cells (n = 5). The thick arrow indicates the orthotopically implanted tumours, and the thin arrow indicated the intrahepatic metastatic foci. f The effect of MHCC97H-derived exosomes on intrahepatic recurrence of HLE tumours (n = 5). Abbreviation: Exo exosome. Data are represented as the mean ± S.D. *P < 0.05 and **P < 0.01. Scale bar, 1.0 mm

Back to article page